Payment overview · 2025
General Payments
$223.59
11 reported records · 6 companies
Healthcare provider profile · identity verified
Pam G Hodges
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PLANTERSVILLE, MS · NPI 1982935623
Verified facts
What the public records show
CMS Open Payments records show Pam G Hodges received $223.59 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.26 | 33.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.24 | 22.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.75 | 19.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.32 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.20 | 8.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.82 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $223.59 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 130 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 90 |
| Gabapentin | Gabapentin | 267 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 219 | 44 |
| Omeprazole | Omeprazole | 215 | 54 |
| Lisinopril | Lisinopril | 149 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 146 | 50 |
| Ozempic | Semaglutide | 130 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 126 | 29 |
| Furosemide | Furosemide | 121 | 43 |
| Potassium Chloride | Potassium Chloride | 101 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 16 |
| Losartan Potassium | Losartan Potassium | 86 | 21 |
| Metformin Hcl Er | Metformin Hcl | 84 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 18 |
| Sertraline Hcl | Sertraline Hcl | 76 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 22 |
| Amoxicillin | Amoxicillin | 71 | 48 |
| Famotidine | Famotidine | 68 | 20 |
| Buspirone Hcl | Buspirone Hcl | 67 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 14 |
| Carvedilol | Carvedilol | 59 | 20 |
| Clonazepam | Clonazepam | 56 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 17 |
| Trazodone Hcl | Trazodone Hcl | 54 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 13 |
| Montelukast Sodium | Montelukast Sodium | 52 | 17 |
| Fluconazole | Fluconazole | 50 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Allopurinol | Allopurinol | 48 | 15 |
| Meloxicam | Meloxicam | 46 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 15 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 16 |
| Valsartan | Valsartan | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Simvastatin | Simvastatin | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Levofloxacin | Levofloxacin | 23 | 18 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $223.59 · 11 records | ABBVIE INC. | ABILIFY MAINTENA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Ozempic, REXULTI, Rybelsus, VIBERZI, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error